pmc logo imageJournal ListSearchpmc logo image
Logo of jcinvestCurrent issueArchiveSubscribe to the JCIAbout the JCIThe Journal of Clinical Investigation
J Clin Invest. 1989 August; 84(2): 665–671.
doi: 10.1172/JCI114213.
PMCID: PMC548930
The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.
M K Hostetter and G M Johnson
Department of Pediatrics, University of Minnesota Medical School, Minneapolis 55455.
Abstract
Myocardial ischemia is characterized by the liberation of adenosine and by complement-mediated inflammation. We have reported that amidated C3, formed when ammonia (NH3) disrupts the thiolester bond of C3, serves as an alternative pathway convertase, generates C5b-9, and stimulates phagocytic oxidative metabolism. We investigated whether the deamination of adenosine by adenosine deaminase in hematopoietic cells might liberate sufficient ammonia to form amidated C3 and thereby trigger complement-mediated inflammation at ischemic sites. In the presence of 4 mM adenosine, NH3 production per erythrocyte (RBC) was equal to that per neutrophil (PMN) (3.3 X 10(-15) mol/cell per h). Because RBC outnumber PMN in normal blood by a thousandfold, RBC are the major source of NH3 production in the presence of adenosine. NH3 production derived only from the deamination of adenosine by the enzyme adenosine deaminase and was abolished by 0.4 microM 2'-deoxycoformycin, a specific inhibitor of adenosine deaminase. When purified human C3 was incubated with 5 X 10(8) human RBC in the presence of adenosine, disruption of the C3 thiolester increased more than twofold over that measured in C3 incubated with buffer, or in C3 incubated with RBC (P less than 0.05). The formation of amidated C3 was abolished by the preincubation of RBC with 2'-deoxycoformycin (P less than 0.001). Amidated C3 elicited statistically significant release of superoxide, myeloperoxidase, and lactoferrin from PMN. Thus, the formation of amidated C3 by RBC deamination of adenosine triggers a cascade of complement-mediated inflammatory reactions.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Images in this article
Click on the image to see a larger version.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Hill, JH; Ward, PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971 Apr 1;133(4):885–900. [PubMed]
  • Hartmann, JR; Robinson, JA; Gunnar, RM. Chemotactic activity in the coronary sinus after experimental myocardial infarction: effects of pharmacologic interventions on ischemic injury. Am J Cardiol. 1977 Oct;40(4):550–555. [PubMed]
  • Maroko, PR; Carpenter, CB; Chiariello, M; Fishbein, MC; Radvany, P; Knostman, JD; Hale, SL. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978 Mar;61(3):661–670. [PubMed]
  • Maclean, D; Fishbein, MC; Braunwald, E; Maroko, PR. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J Clin Invest. 1978 Mar;61(3):541–551. [PubMed]
  • Pinckard, RN; O'Rourke, RA; Crawford, MH; Grover, FS; McManus, LM; Ghidoni, JJ; Storrs, SB; Olson, MS. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest. 1980 Nov;66(5):1050–1056. [PubMed]
  • Pinckard, RN; Olson, MS; Giclas, PC; Terry, R; Boyer, JT; O'Rourke, RA. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975 Sep;56(3):740–750. [PubMed]
  • Giclas, PC; Pinckard, RN; Olson, MS. In vitro activation of complement by isolated human heart subcellular membranes. J Immunol. 1979 Jan;122(1):146–151. [PubMed]
  • Kovacsovics, T; Tschopp, J; Kress, A; Isliker, H. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol. 1985 Oct;135(4):2695–2700. [PubMed]
  • Peitsch, MC; Kovacsovics, TJ; Tschopp, J; Isliker, H. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. J Immunol. 1987 Mar 15;138(6):1871–1876. [PubMed]
  • Rubio, R; Berne, RM; Katori, M. Release of adenosine in reactive hyperemia of the dog heart. Am J Physiol. 1969 Jan;216(1):56–62. [PubMed]
  • Gordon, DL; Krueger, RA; Quie, PG; Hostetter, MK. Amidation of C3 at the thiolester site: stimulation of chemiluminescence and phagocytosis by a new inflammatory mediator. J Immunol. 1985 May;134(5):3339–3345. [PubMed]
  • Nath, KA; Hostetter, MK; Hostetter, TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest. 1985 Aug;76(2):667–675. [PubMed]
  • Tolins, JP; Hostetter, MK; Hostetter, TH. Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest. 1987 May;79(5):1447–1458. [PubMed]
  • Rogler-Brown, T; Agarwal, RP; Parks, RE., Jr Tight binding inhibitors--VI. Interactions of deoxycoformycin and adenosine deaminase in intact human erythrocytes and sarcoma 180 cells. Biochem Pharmacol. 1978;27(19):2289–2296. [PubMed]
  • Agarwal, RP; Spector, T; Parks, RE., Jr Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359–367. [PubMed]
  • Henderson, JF; Brox, L; Zombor, G; Hunting, D; Lomax, CA. Specificity of adenosine deaminase inhibitors. Biochem Pharmacol. 1977 Nov 1;26(21):1967–1972. [PubMed]
  • Agarwal, RP. Inhibitors of adenosine deaminase. Pharmacol Ther. 1982;17(3):399–429. [PubMed]
  • Steinbuch, M; Audran, R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969 Nov;134(2):279–284. [PubMed]
  • Laemmli, UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. [PubMed]
  • Janatova, J; Lorenz, PE; Schechter, AN; Prahl, JW; Tack, BF. Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry. 1980 Sep 16;19(19):4471–4478. [PubMed]
  • Tack, BF; Harrison, RA; Janatova, J; Thomas, ML; Prahl, JW. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5764–5768. [PubMed]
  • Gordon, DL; Johnson, GM; Hostetter, MK. Ligand-receptor interactions in the phagocytosis of virulent Streptococcus pneumoniae by polymorphonuclear leukocytes. J Infect Dis. 1986 Oct;154(4):619–626. [PubMed]
  • Pick, E; Mizel, D. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods. 1981;46(2):211–226. [PubMed]
  • Webster, RO; Henson, PM. Rapid micromeasurement of neutrophil exocytosis. Inflammation. 1978 Jun;3(2):129–135. [PubMed]
  • Hetherington, SV; Spitznagel, JK; Quie, PG. An enzyme-linked immunoassay (ELISA) for measurement of lactoferrin. J Immunol Methods. 1983 Dec 16;65(1-2):183–190. [PubMed]
  • Van Belle, H. Uptake and deamination of adenosine by blood. Species differences, effect of pH, ions, temperature and metabolic inhibitors. Biochim Biophys Acta. 1969 Oct 7;192(1):124–132. [PubMed]
  • Hostetter, MK; Krueger, RA; Schmeling, DJ. The biochemistry of opsonization: central role of the reactive thiolester of the third component of complement. J Infect Dis. 1984 Nov;150(5):653–661. [PubMed]
  • Isenman, DE; Kells, DI; Cooper, NR; Müller-Eberhard, HJ; Pangburn, MK. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry. 1981 Jul 21;20(15):4458–4467. [PubMed]
  • von Zabern, I; Nolte, R; Vogt, W. Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b. Scand J Immunol. 1981;13(5):413–431. [PubMed]
  • Schreiber, RD; Pangburn, MK; Müller-Eberhard, HJ. C3 modified at the thiolester site: acquisition of reactivity with cellular C3b receptors. Biosci Rep. 1981 Nov;1(11):873–880. [PubMed]
  • Hostetter, MK; Gordon, DL. Biochemistry of C3 and related thiolester proteins in infection and inflammation. Rev Infect Dis. 1987 9(1):97–109.Jan–Feb; [PubMed]
  • Rubio, R; Berne, RM. Release of adenosine by the normal myocardium in dogs and its relationship to the regulation of coronary resistance. Circ Res. 1969 Oct;25(4):407–415. [PubMed]
  • Parks, RE, Jr; Crabtree, GW; Kong, CM; Agarwal, RP; Agarwal, KC; Scholar, EM. Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes. Ann N Y Acad Sci. 1975 Aug 8;255:412–434. [PubMed]
  • Agarwal, RP. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells. Biochem Pharmacol. 1980 Feb;29(2):187–193. [PubMed]
  • Spiers, AS; Moore, D; Cassileth, PA; Harrington, DP; Cummings, FJ; Neiman, RS; Bennett, JM; O'Connell, MJ. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med. 1987 Apr 2;316(14):825–830. [PubMed]
  • Simpson, PJ; Todd, RF, 3rd; Fantone, JC; Mickelson, JK; Griffin, JD; Lucchesi, BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988 Feb;81(2):624–629. [PubMed]
  • Bolli, R; Patel, BS; Jeroudi, MO; Lai, EK; McCay, PB. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone. J Clin Invest. 1988 Aug;82(2):476–485. [PubMed]